Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
ALLEGRA GENERIC IN US
 

Allegra generic to be launched in US

Generic version of rhinitis drug fexofenedine will be soon launched in the US.

 

BY OUR PHARMA CORRESPONDENT

13 September,2005: Barr Pharmaceuticals, Inc and Teva Pharmaceutical Industries Ltd have entered into an agreement for the launch of Fexofenadine Hydrochloride 30 mg, 60 mg and 180 mg Tablets.

The pills are the generic equivalent of Aventis Pharmaceuticals’ Allegra tablets. Allegra tablets had annual sales of approximately $1.4 billion, based on IMS data for the twelve months ended June 2005.

Under the agreement, Barr has taken the regulatory steps necessary to permit Teva to obtain final U.S. Food and Drug Administration approval of Teva’s fexofenadine hydrochloride tablets and to sell the product within Barr’s 180-day exclusivity. In return, Barr will receive a negotiated percentage of the gross profit of Teva’s product, both during and after the exclusivity period. Teva will record the revenues resulting from sales of the product and remit the negotiated percentage of its gross profit to Barr. 

In June 2004 Barr and Teva were granted summary judgment of non-infringement with respect to three patents, and were granted summary judgment of invalidity on an additional patent in the case in April 2005. Several patents remain in the litigation. Although no trial date has been set, the companies expect that a trial will occur sometime in 2006. 

Barr was the first generic applicant to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV patent challenge on the patents related to the Allegra tablet product and consequently was granted 180 days exclusivity, which it has now transferred to Teva. 

Allegra (fexofenadine hydrochloride) is indicated for the relief of symptoms associated with seasonal allergic rhinitis and for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. 

Barr Pharmaceuticals, Inc is a holding company whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceuticals.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generics and active pharmaceutical ingredients. Close to 90% of Teva’s sales are in North America and Europe.

BY OUR PHARMA CORRESPONDENT

 

   Pharma Home
LATEST UPDATES

Chinese herbal products could be dangerous: UK 

Knock, knock! It's bird flu at the door

Spider anti-venom to be stocked in UAE hospital 

US may ban animal protein in cattle feed to safeguard against mad cow 

Dr Reddy's nizatidine generic gets FDA nod

Late-onset Pompe disease drug goes on trial

First biologic to treat ulcerative colitis gets US FDA okay

Diverticulitis orally dissolving pill from KV Pharma's  hits the market

Impax delisted from Nasdaq

US FDA okays Lupin's cephalexin

Hepatitis C combo therapy to get priority review in Japan

Lung cancer vaccine trials promising: Introgen

Sugar-free pill Actiq for cancer pain

39 drug firms sued over price rigging in California

Anti fungal terbinafine launched in Europe: Actavis

HIV entry blocking drug data encouraging: Progenics

Allegra generic to be launched in US

Long-acting pain drug data positive: Pain Therapeutics

New kidney cancer drug seeks EU nod

Inhaled insulin may get US FDA clearance

A vaccine against fungus is on way

Enzyme stops progression of HIV in survivors, confirms study

Aclasta found faster-acting in Paget's disease treatment

Beta blocker can start therapy in heart failure: Merck

Halobetasol generic launched in US

Anemia drug darbepoetin's late-stage studies begin: Amgen

Cholesterol generic gets marketing nod in US: Par

Aricept for severe Alzheimer’s disease too: Eisai

Bone regeneration trials begin in US:Mesoblast

New dye to detect early Alzheimer's

Breast forming gene discovered

Thyroid drug to be supplied by IVAX in US

Rituxan, cancer drug can treat rheumatoid arthritis

Yasminelle, low-dose oral contraceptive approved in the Netherlands

Fluarix, anti-flu shot by Glaxo approved

Increlex, drug to treat `abnormally short’ kids approved in US

Anti-HIV drugs prices cut: Gilead

US FDA approves Takeda’s drug combo for type 2 diabetes

Novartis’ drug for breast cancer recurrence to be given priority review in US

US puts off decision on contraceptive pill again

Shire’s ADHD drug Adderall back on list in Canada

WHO calls for emergency action to halt TB in Africa

Some of the Vioxx suits may be settled: Merck

Nasdaq delists Able on bankruptcy filing

Hospira ships ceftriaxone generics to US

Renovis stops sciatica drug studies

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us